Atomi Financial Group Inc. Has $1.58 Million Stock Holdings in Danaher Co. (NYSE:DHR)

Atomi Financial Group Inc. reduced its position in shares of Danaher Co. (NYSE:DHR) by 19.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,892 shares of the conglomerate’s stock after selling 1,633 shares during the period. Atomi Financial Group Inc.’s holdings in Danaher were worth $1,582,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. FMR LLC raised its holdings in shares of Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after acquiring an additional 535,254 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Danaher by 40,196.5% in the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after acquiring an additional 428,897 shares during the last quarter. Montrusco Bolton Investments Inc. boosted its stake in shares of Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after purchasing an additional 397,671 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec grew its holdings in shares of Danaher by 82.4% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 653,375 shares of the conglomerate’s stock valued at $181,651,000 after purchasing an additional 295,187 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Price Performance

Shares of DHR opened at $244.18 on Wednesday. The firm has a market cap of $176.36 billion, a PE ratio of 46.60, a price-to-earnings-growth ratio of 4.30 and a beta of 0.83. Danaher Co. has a 52-week low of $225.42 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The business’s 50 day moving average price is $234.75 and its two-hundred day moving average price is $253.50.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period last year, the company posted $2.02 earnings per share. On average, equities analysts anticipate that Danaher Co. will post 7.49 EPS for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.44%. Danaher’s payout ratio is currently 20.61%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on DHR shares. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a research report on Friday, December 13th. KeyCorp increased their target price on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a report on Thursday, October 31st. Finally, Stifel Nicolaus raised their price objective on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.